New insider activity at Codexis ( (CDXS) ) has taken place on March 7, 2025.
Opaleye Management Inc., a significant shareholder, has made a notable investment by purchasing 65,000 shares of Codexis stock, valued at $172,000.
Recent Updates on CDXS stock
Codexis has recently held its Q4 earnings call, showcasing a positive outlook with advancements in its ECO Synthesis platform and Pharma Biocatalysis business. Despite challenges in revenue generation without PAXLOVID and declining gross margins due to changes in product mix, the company projects double-digit revenue growth for 2025, driven by its ECO Synthesis platform. Codexis has made significant progress in enzymatic siRNA synthesis and aims to secure revenue-generating contracts by early Q2 2025. The company reported a reduction in net loss for 2024, reflecting improved financial management. Codexis is focused on expanding its commercial capabilities and expects to achieve positive cash flow by the end of 2026.
More about Codexis
YTD Price Performance: -45.40%
Average Trading Volume: 803,390
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $222M
Questions or Comments about the article? Write to editor@tipranks.com